Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.01 · 8-K

Lexaria Bioscience Corp.

LEXXNASDAQEQUITYCurrent

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Delisting Notification On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain…

Filed Aug 10, 2026Accepted Aug 10, 2026, 5:00 PM EDTCIK 1348362Accession 0001640334-26-001302
Share

Company context

Lexaria is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.

Current securities

Historical securities (2)

Recent company filings

  1. EFFECT filingOct 13, 2026
  2. 424B3 filingOct 13, 2026
  3. S-3 filingOct 2, 2026
  4. D filingSep 21, 2026
  5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 9, 2026

Registered securities in this filing

LEXARIA BIOSCIENCE CORP. · 8-K · Filed 2026-08-10

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
LEXX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-08-04to2026-08-04

Dimensions: Not supplied

Accession 000164033426001302 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 3.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.01Item 3.01 - Notice of Delisting
Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Delisting Notification On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain a $1.00 minimum bid price, (the “Bid Price Requirement”) within the 180 day compliance period provided under Nasdaq Listing Rule 5810(c)(3)(A), it would be delisted from the Nasdaq, subject to any request for a hearing to appeal such determination, which hearing request would stay the suspension of the Company’s shares from being delisted. In anticipation of the Notification, the Company completed a reverse stock split on August 3, 2026 (as announced on July 30, 2026) and, since that time, the Company’s shares of common stock have been trading on Nasdaq under CUSIP number 52886N604 with a minimum bid price that is currently above the Bid Price Requirement. The Company has also filed its request for a hearing and paid the required fee in order to suspend the delisting of the Company’s shares from Nasdaq and to allow for the additional trading days necessary to regain the Bid Price Requirement. As of the date and time of this filing, the Company expects to regain compliance with the Nasdaq rules and requirements prior to any potential hearing date and expects its shares will remain trading on Nasdaq without interruption.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.